Global Graft Versus Host Disease Treatment Market 2023-2030: Monoclonal Antibodies Lead Surge in Graft Versus Host Disease Treatment Market, Monitored by Comprehensive Vendor Analysis


Dublin, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The "Global Graft Versus Host Disease Treatment Market by Disease Type, Product, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.

The Global Graft Versus Host Disease Treatment Market size was estimated at USD 1.70 billion in 2022, USD 1.87 billion in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.38% to reach USD 3.76 billion by 2030.

In this report, 2018 to 2021 are considered historical years, 2022 is the base year, 2023 is the estimated year, and years from 2024 to 2030 are considered as the forecast period.

The report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share.

The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Market Segmentation & Coverage:

This research report categorizes the Global Graft Versus Host Disease Treatment Market in order to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, the market is studied across Acute Graft Versus Host Disease and Chronic Graft Versus Host Disease. The Chronic Graft Versus Host Disease is projected to witness a significant market share during the forecast period.
  • Based on Product, the market is studied across Corticosteroids, Monoclonal Antibodies, and Tyrosine Kinase Inhibitors. The Monoclonal Antibodies are projected to witness a significant market share during the forecast period.
  • Based on End-User, the market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Hospital Pharmacies are projected to witness a significant market share during the forecast period.
  • The Americas commanded the largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

The report provides insights on the following pointers:

  1. Market Penetration: Provides comprehensive information on the market offered by the key players
  2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
  3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
  5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

Market Dynamics

Drivers

  • Increases in air cargo revenue and tonnage to boost bulky and heavy cargo
  • A growing number of allogeneic transplantations
  • Rising number of patients undergoing allogeneic hematopoietic stem cell transplants

Restraints

  • Disruption through digitization and demand to speed up the movement of goods across the globe
  • Competition from other transport modes
  • Clinical advancements in the treatment procedure

Opportunities

  • Growth of cargo services in emerging markets
  • Technological developments in new aircraft technologies and digitization

Challenges

  • Trade tensions and increasing industry regulation

Competitive Portfolio

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • ElsaLys Biotech SA
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt LLC
  • Merck KGaA
  • Mesoblast Limited
  • Neovii Pharmaceuticals AG
  • Novartis AG
  • Ocugen, Inc.
  • Pfizer Inc
  • Pluristem Therapeutics Inc.
  • Sanofi S.A.
  • Soligenix, Inc.

Key Attributes:

Report AttributeDetails
No. of Pages187
Forecast Period2023 - 2030
Estimated Market Value (USD) in 2023$1.87 Billion
Forecasted Market Value (USD) by 2030$3.76 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal


For more information about this report visit https://www.researchandmarkets.com/r/sl5et7

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

 
Global Graft Versus Host Disease Treatment Market

Contact Data